Physician profile
Roberta Louise Salveson
NPI 1336260280
$45,005.30
in general payments reported to CMS, 2019-2025
13 companies · $8,496 in 2025
The $8,496 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $917 · 2022: $8,379 · 2023: $10K · 2024: $17K · 2025: $8,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,605 · Travel and Lodging: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,813.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,163.00 |
| Food and Beverage | $3,605.35 |
| Travel and Lodging | $3,127.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $41,462.39 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,129.26 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,114.77 | 2022-2025 | Vpriv |
| Ptc Therapeutics, INC. | $318.52 | 2021-2025 | Sephience |
| Horizon Therapeutics Plc | $250.00 | 2021-2023 | Ravicti |
| Biomarin Pharmaceutical INC. | $235.64 | 2022-2025 | Voxzogo 1.2mg, Vimizim |
| Chiesi USA, INC. | $158.86 | 2025 | Elfabrio |
| Amgen INC. | $125.00 | 2024 | Ravicti |
| Sanofi Pasteur INC. | $125.00 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $43.04 | 2023 | Dojolvi |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $25.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.33 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Salveson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.